Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Luca Laurenti, Francesca R. Mauro, Stefano Molica, Agostino Cortelezzi, Angelo M. Carella, Francesco Zaja, Annalisa Chiarenza, Francesco Angrilli, Francesco Nobile, Roberto Marasca, Caterina Musolino, Maura Brugiatelli, Alfonso Piciocchi, Marco Vignetti, Paola Fazi, Giuseppe Gentile, Maria S. De Propris, Irene Della Starza, Marilisa Marinelli, Sabina ChiarettiIlaria Del Giudice, Mauro Nanni, Francesco Albano, Antonio Cuneo, Anna Guarini, Robin Foà

Research output: Contribution to journalArticle

7 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile'. Together they form a unique fingerprint.

Medicine & Life Sciences